The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.
Qiangyun LiuYixuan ZhangMiaowen LiuRuoxin XuFengming YiYiping WeiShuqiang ZhuWenxiong ZhangPublished in: World journal of surgical oncology (2021)
The combination of pembrolizumab with conventional chemotherapy is an effective therapeutic schedule with acceptable and manageable efficacy and toxicity in patients with SCLC. More high-quality and well-designed RCTs with large sample sizes are warranted to further validate our findings.
Keyphrases
- small cell lung cancer
- systematic review
- locally advanced
- advanced non small cell lung cancer
- double blind
- open label
- meta analyses
- oxidative stress
- placebo controlled
- squamous cell carcinoma
- rectal cancer
- chemotherapy induced
- phase ii
- randomized controlled trial
- clinical trial
- human health
- bone marrow
- epidermal growth factor receptor
- climate change